Rankings
▼
Calendar
REVB Q4 2024 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
REVB
Revelation Biosciences, Inc.
$2M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$26,964
-28.2% YoY
Gross Profit
$13,482
50.0% margin
Operating Income
-$2M
-6504.6% margin
Net Income
-$2M
-6400.1% margin
EPS (Diluted)
$-4.98
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$72,566
Balance Sheet
Total Assets
$7M
Total Liabilities
$2M
Stockholders' Equity
$5M
Cash & Equivalents
$6M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$26,964
$37,574
-28.2%
Gross Profit
$13,482
$18,787
-28.2%
Operating Income
-$2M
-$2M
+24.6%
Net Income
-$2M
-$2M
+21.7%
← FY 2024
All Quarters
Q1 2025 →